Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02242071

Enrollment

Registered

2014-09-16

Start date

2008-12-31

Completion date

2016-09-30

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Keywords

Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Autologous Mononuclear Cell therapy, Stem cells

Brief summary

The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.

Interventions

BIOLOGICALStem Cell

intrathecal autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with the diagnosis of definite Motor Neuron Disease/amyotrophic lateral sclerosis. * Age 18-80 years

Exclusion criteria

* HIV/HBV/HCV * Malignancies * Bleeding tendencies * Pneumonia * Renal failure * Severe liver dysfunction * Severe anemia \[hb \< 8\] * Any bone marrow disorder * Space occupying lesion in brain * Pregnancy and lactation * Other acute medical conditions/infections such as respiratory infection and pyrexia * left ventricular ejection fraction \< 25% * Patient on artificial ventilatory support

Design outcomes

Primary

Measure	Time frame
Amyotrophic Lateral Sclerosis Functional rating scale-revised	2 years

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026